摘要
目的：探讨强化阿托伐他汀治疗对非ST段抬高型急性冠脉综合征患者同型半胱氨酸（ Hcy）和N末端B型脑钠肽（ NT－proBNP）的影响。方法120例非ST段抬高型急性冠脉综合征患者按数字表法随机分为观察组60例、对照组60例，观察组在常规治疗的基础上每晚加用阿托伐他汀40 mg治疗，对照组在常规治疗基础上每晚加用阿托伐他汀20 mg治疗。两组共治疗2个月，比较两组治疗前后血浆Hcy和NT－proBNP的变化。结果观察组、对照组治疗前Hcy分别为（25．5±8．6）μmol／L、（26．3±9．1）μmol／L，治疗后分别为（10．3±4．7）μmol／L、（16．9±7．1）μmol／L；观察组、对照组治疗前NT－proBNP分别为（374．7±39．2） ng／L、（359．6±36．1）ng／L，治疗后分别为（127．4±15．3）ng／L、（237．1±24．3）ng／L。两组治疗后血浆Hcy和NT－proBNP均比治疗前明显降低，治疗后观察组较对照组降低更明显（t＝6．004、29．591，均P＜0．05）。两组患者均未见因明显的肝酶及肌酶升高而导致停药情况的发生。结论强化阿托伐他汀治疗可以明显降低非ST段抬高型急性冠脉综合征患者血浆Hcy和NT－proBNP。
Objective To study effects of strengthened atorvastatin treatment on homocysteine（ Hcy） and N-terminal B-type natriuretic peptide（ NT-proBNP） in patients with non-ST-segment elevation acute coronary syndrome. Methods 120 patients with non-ST-segment elevation acute coronary syndrome were randomly divided into the two groups,the observation group（n=60 cases） and the control group（n=60 cases）.The patients in the observation group were treated through the basis of conventional therapy plus atorvastatin 40mg/night treatment,while the patients in the control group were treated through the basis of conventional therapy plus atorvastatin 20mg/night treatment. They were all treated for two months.Plasma Hcy and NT-proBNP were detected before and after treatment.Results Hcy in the observation group and the control group before treatment were （ 25.5 ±8.6 ）μmol/L and （ 26.3 ± 9.1）μmol/L,respectively,（10.3 ±4.7）μmol/L and （16.9 ±7.1）μmol/L after treatment.NT-proBNP in the obser-vation group and the control group before treatment were （374.7 ±39.2）ng/L and （359.6 ±36.1）ng/L,respective-ly,（127.4 ±15.3）ng/L and （237.1 ±24.3）ng/L after treatment.After treatment,plasma Hcy and NT-proBNP were significantly reduced than those before treatment and after treatment（P〈0.05）.During follow-up,the two groups showed no elevated liver enzymes and muscle enzymes and lead to withdrawal from happening.Conclusion Strength-ened atorvastatin treatment can significantly reduce Hcy and NT-proBNP in patients with non-ST-segment elevation acute coronary syndrome.
出处
《中国基层医药》
CAS
2014年第24期3759-3761,共3页
Chinese Journal of Primary Medicine and Pharmacy
